Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients

Phase 3TerminatedNCT01599754

SFJ Pharma Ltd. II724 enrolled

Overview

The purpose of this trial is to determine if adjuvant therapy with axitinib will prevent or delay the recurrence of renal cell cancer after surgery to remove the primary tumor in high risk patients.

This is a prospective, randomized, double blind placebo controlled Phase 3 trial of oral axitinib starting at 5 mg twice daily given 3 years vs. placebo. Approximately 700 patients will be randomized in a 1:1 ratio between axitinib vs placebo.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Enrollment

724

Conditions

Clear Cell Renal Carcinoma

Interventions

AxitinibDRUG

Axitinib 5 mg twice daily

PlaceboDRUG

Placebo twice daily

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patients must be treated by nephrectomy and patients must meet all of the following inclusion criteria to be eligible for enrollment into the trial: 1. Patients must have no evidence of macroscopic residual disease or metastatic disease. 2. Male or female, age \>=18 years (age \>=20 years in Japan, Korea and Taiwan). 3. Patients must be diagnosed with one of the following based on American Joint Committee on Cancer (AJCC) TNM staging version 2010, Eastern Collaborative Oncology Group (ECOG) performance status (PS): * pT2, pN0 or pNx, M0 and ECOG PS 0-1 * pT3, pN0 or pNx, M0 and ECOG PS 0-1 * pT4, pN0 or pNx, M0 and ECOG PS 0-1 * Any pT, pN1, M0 and ECOG PS 0-1 4. Patients must have histologically confirmed preponderant, defined as \>50%, clear cell RCC. 5. Patients must not have received any previous systemic (includes chemotherapeutic, hormonal, or immunotherapeutic) treatment for RCC. 6. Patients must not have received any previous anti angiogenic treatment. 7. Patients must have adequate organ function. Exclusion Criteria 1. Histologically undifferentiated carcinomas, sarcomas, collecting duct carcinoma, lymphoma, or patients with any metastatic renal sites. 2. National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 hemorrhage \<4 weeks of date of randomization. 3. Diagnosis of any non-RCC malignancy within the 5 years from date of randomization, except basal cell carcinoma, squamous cell skin cancer, or in situ carcinoma of the cervix uteri that has been adequately treated with no evidence of recurrent disease for 12 months. 4. Any of the following within the 12 months prior to study drug administration: myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack and 6 months for deep vein thrombosis or pulmonary embolism. 5. Gastrointestinal abnormalities

Locations (106)

Outcomes

Primary Outcomes

Disease Free Survival (DFS) as Assessed by Blinded Independent Review Committee (IRC)

DFS is defined as time interval from the date of randomization to first date of recurrence/relapse (distant or local recurrence of \[RCC\] or occurrence of a secondary malignancy {occurrence of a second primary cancer other than RCC} or death). For participants with no DFS event, DFS was censored at date of last scan prior to time of analyses. Participants alive who did not have post-baseline disease assessments, DFS was censored at randomization. Participants who received further anti-tumor therapy prior to recurrence or occurrence of a secondary malignancy or death, DFS was censored on date of last scan prior to taking anti-tumor medication. Participants who missed 2 or more consecutive tumor scans immediately followed by an event were censored at date of last objective tumor assessment prior to missing/not readable scan.

Time frame: From randomization date up to first date of recurrence or the occurrence of a secondary malignancy or death (up to 5 years)

Secondary Outcomes

Overall Survival (OS)

OS defined as the time from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive. Participants lacking data beyond randomization had their survival times censored at randomization.

Time frame: From randomization date until death due to any cause (up to 5 years)

Number of Participants With Treatment-Emergent Adverse Events (AE) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious adverse events.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Unnamed facility

La Jolla, California, United States

Unnamed facility

Los Angeles, California, United States

Unnamed facility

Palo Alto, California, United States

Unnamed facility

Pleasant Hill, California, United States

Unnamed facility

Denver, Colorado, United States

Unnamed facility

Washington D.C., District of Columbia, United States

Unnamed facility

Ocala, Florida, United States

Unnamed facility

Atlanta, Georgia, United States

Unnamed facility

Annapolis, Maryland, United States

Unnamed facility

Baltimore, Maryland, United States

...and 96 more locations